Previous 10 | Next 10 |
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Another huge week of earnings is on tap with more than a quarter of S&P 500 companies due to report, including compe...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Nikolay Pandev/E+ via Getty Images A couple of household names anchored the earnings releases on Wednesday morning. Home products retailer Bed Bath & Beyond (BBBY) and packaged foods maker General Mills (GIS) announced their quarterly results. AMMO, Inc. (POWW) also issued its financial f...
UNIONDALE, N.Y., June 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today anno...
Angion Biomedica (ANGN): Q1 GAAP EPS of -$1.56.Revenue of $0.37M (-57.5% Y/Y) misses by $1.52M.Press Release For further details see: Angion Biomedica misses on revenue
UNIONDALE, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today provid...
Angion Biomedica (ANGN) and Vifor Pharma have completed enrollment for Angion’s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI).This indication is part of the ANG-3777 license agreement both parties signed in...
UNIONDALE, N.Y. and ST. GALLEN, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion’s AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk of cardiac-surgery associated a...
Angion is a recent IPO. It has an ongoing phase 3 trial with near-term data readout. Cash balance is a little low. For further details see: Angion Biomedica: Interesting New IPO With Late Stage Asset Targeting A Novel Indication
News, Short Squeeze, Breakout and More Instantly...
Angion Biomedica Corp. Company Name:
ANGN Stock Symbol:
NASDAQ Market:
NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ:I...
NEW YORK, NY / ACCESSWIRE / March 19, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cardiovascular Systems, Inc. (NASDAQ...